Premarin vs Veozah: How to Switch and Which One Fits Your Menopause Stage

Import from "@/components/mdx"

What Are These Two Drugs and How Do They Work Differently?

Premarin and Veozah both reduce hot flashes, but they operate through completely different mechanisms. Premarin replaces the estrogen your ovaries stop making during menopause. Veozah blocks a brain signaling molecule that triggers heat-dissipation responses in the absence of estrogen. That mechanistic difference is what drives every downstream decision about who should take which drug.

Premarin: Replacing the Hormone

Premarin is conjugated equine estrogens (CEE), derived from the urine of pregnant mares, and has been prescribed since 1942. The standard dose for vasomotor symptom relief is 0.625 mg taken orally once daily, though a lower starting dose of 0.3 mg is sometimes used for women who are newly postmenopausal or more estrogen-sensitive. As estrogen, it crosses multiple tissue targets: it reduces hot flash frequency and severity, slows bone turnover, improves vaginal tissue integrity, and can affect mood, sleep architecture, and cardiovascular risk.

Because Premarin is systemic estrogen, any woman with a uterus who takes it requires a progestogen alongside it to protect the uterine lining from estrogen-driven proliferation. Women who have had a hysterectomy can use CEE alone.

Veozah: A Hormone-Free Approach

Fezolinetant (Veozah) received FDA approval in May 2023 as the first NK3 receptor antagonist approved for vasomotor symptoms. During menopause, low estrogen causes increased activity of neurokinin B (NKB) on the KNDy neurons in the hypothalamus. Those neurons are responsible for the thermoregulatory "set point" instability that produces hot flashes. Fezolinetant at 45 mg once daily blocks the NK3 receptor these neurons use, narrowing the thermal neutral zone without adding any exogenous hormone.

No progestogen is needed. No effect on breast tissue, uterine lining, or estrogen-sensitive cancers. This makes Veozah a genuinely different category of treatment, not simply a weaker or safer substitute for estrogen.

How Well Do They Actually Work? The Trial Data

No head-to-head randomized controlled trial has directly compared Premarin to Veozah. The data below comes from separate key trials, which limits direct comparison. Differences in trial populations, endpoints, and definitions of "moderate-to-severe" hot flashes mean the numbers are not interchangeable.

The WHI Estrogen-Alone Arm

The Women's Health Initiative estrogen-alone arm enrolled 10,739 postmenopausal women who had previously had a hysterectomy and compared CEE 0.625 mg/day to placebo. Vasomotor symptom reduction was strong: CEE produced a 74.6% reduction in hot flash frequency at 12 months compared to about 51% for placebo. CEE also reduced hip fracture risk and improved sleep quality in this cohort. However, the WHI also defined the cardiovascular and stroke risk profile that now informs prescribing: CEE increased stroke risk (hazard ratio 1.39) and did not reduce coronary heart disease in the full trial population, though absolute risk differences in younger postmenopausal women are small.

The WHI enrolled women aged 50 to 79, with a mean age of 63, which is meaningfully older than the women typically presenting for vasomotor symptom treatment today. The Menopause Society's 2022 position statement notes that for women under 60 or within 10 years of menopause onset, the benefit-risk ratio for hormone therapy is favorable in the absence of contraindications.

SKYLIGHT-1: The Fezolinetant Key Trial

SKYLIGHT-1, published in The Lancet in 2023, randomized 501 postmenopausal women with at least seven moderate-to-severe hot flashes per day to fezolinetant 30 mg, fezolinetant 45 mg, or placebo. At week 12, fezolinetant 45 mg reduced the frequency of moderate-to-severe vasomotor symptoms by 63% versus 44% for placebo, and severity scores dropped significantly. By week 52, the treatment effect was sustained. The 30 mg dose also worked but showed slightly less separation from placebo, which is why 45 mg was the dose selected for approval.

Critically, SKYLIGHT-1 enrolled women who were not candidates for or did not want hormone therapy, so the trial population differs meaningfully from typical CEE trials. The evidence gap matters here: we do not have a direct comparison of how fezolinetant performs against CEE in the same women at the same time point.

What the Numbers Mean in Practice

| | Premarin (CEE 0.625 mg) | Veozah (fezolinetant 45 mg) | |---|---|---| | Hot flash frequency reduction | ~74% at 12 months (WHI) | ~63% at 12 weeks (SKYLIGHT-1) | | Hot flash severity reduction | Significant vs placebo | Significant vs placebo | | Bone protection | Yes (FDA-approved indication) | No | | Vaginal dryness / GSM relief | Yes | No direct effect | | Requires progestogen | Yes (intact uterus) | No | | Mechanism | Hormonal | Non-hormonal | | Key safety signal | CV/stroke risk; breast risk with combined HT | Liver enzyme elevation; contraindicated in hepatic impairment |

Numbers from trials with different populations are placed side by side for orientation only, not as a head-to-head conclusion.

Who Should Use Which Drug? A Life-Stage and Condition Guide

Early Perimenopause (Still Cycling, Irregular Periods)

Veozah is not indicated during perimenopause when you are still having periods, and neither drug should be used as contraception. Premarin is similarly not appropriate as the primary vasomotor symptom treatment for perimenopausal women who are still potentially ovulating, because systemic estrogen-alone can disrupt cycle regulation and will not prevent pregnancy. ACOG recommends low-dose combined oral contraceptives or a levonorgestrel IUD for perimenopausal women who want both contraception and vasomotor symptom relief, particularly in the early perimenopause phase.

Postmenopausal Women Without Contraindications to Estrogen

If you are postmenopausal, have no history of estrogen-receptor-positive breast cancer, no personal history of blood clots or stroke, and no active liver disease, CEE (Premarin) typically offers broader coverage. You get vasomotor symptom relief, bone protection, and, if applicable, GSM improvement, often through one prescription. Women who also have vaginal atrophy, recurrent urinary tract infections related to low estrogen, or documented osteopenia may find CEE's multi-system effects meaningful.

Women With Estrogen Contraindications

Veozah was designed for this group. Women with:

• A personal history of ER-positive breast cancer or strong family history prompting oncologist-advised avoidance of estrogen
• A history of deep vein thrombosis or pulmonary embolism
• Active liver disease (note: Veozah itself is contraindicated in moderate-to-severe hepatic impairment, so liver function must be evaluated before starting)
• Unexplained vaginal bleeding
• Known or suspected estrogen-dependent malignancy

...now have an evidence-based, FDA-approved non-hormonal option for moderate-to-severe hot flashes that goes beyond the older gabapentin or antidepressant off-label alternatives. The SKYLIGHT-1 population included breast cancer survivors and women who declined hormones, and the trial did not show endocrine or uterine safety signals.

Women With PCOS

Polycystic ovary syndrome does not end at menopause. Postmenopausal women with a history of PCOS may carry residual metabolic risks: higher baseline cardiovascular risk, insulin resistance, and in some cases ongoing androgen excess. The choice between CEE and fezolinetant in this group depends more on individual metabolic profile and cardiometabolic risk than on PCOS history alone. The evidence base for either drug specifically in postmenopausal women with prior PCOS is thin, and this is an area where data in women is extrapolated rather than directly studied.

Pregnancy, Lactation, and Contraception

Both Premarin and Veozah are contraindicated in pregnancy.

Premarin in Pregnancy and Lactation

CEE carries FDA labeling that contraindicates use during pregnancy. Estrogen exposure in the first trimester has been associated with fetal anomalies in some observational studies, though causality is difficult to establish. CEE is also not recommended during breastfeeding: estrogen suppresses lactation and may reduce milk supply. If you are postmenopausal and on Premarin, pregnancy is not a concern. But perimenopausal women who still have ovulatory cycles and are prescribed CEE for another indication must use reliable non-hormonal or barrier contraception because CEE does not prevent ovulation.

Veozah in Pregnancy and Lactation

Fezolinetant is contraindicated in pregnancy. Animal reproductive toxicity studies showed embryofetal harm at exposures above the clinical dose. There are no human pregnancy data. Lactation data do not exist. Because Veozah is indicated only for postmenopausal women, the practical pregnancy risk is low, but any perimenopausal woman with residual fertility who is prescribed Veozah off-label should be counseled on reliable contraception.

A Note on Contraception Overlap

Neither drug provides contraception. Women in late perimenopause who still have any chance of ovulation should be counseled that standard guidance recommends contraception until 12 consecutive months without a period (for women over 50) or 24 months (for women under 50), per The Menopause Society's guidance on contraception in perimenopause.

Side Effects: What to Expect From Each

Premarin Side Effects

Common side effects of CEE include breast tenderness, bloating, and spotting (in women with intact uteri not taking a progestogen). The cardiovascular and venous thromboembolism signals from the WHI are the most clinically significant long-term concerns. The oral route of CEE has first-pass hepatic metabolism, which means it raises sex hormone binding globulin and C-reactive protein more than transdermal estradiol does. For women with elevated triglycerides or a clotting history, transdermal estradiol (not Premarin) is the preferred estrogen form.

Veozah Side Effects

In SKYLIGHT-1 and the open-label extension, the most common adverse events for fezolinetant were abdominal pain (5.7%) and diarrhea (4.2%). Liver enzyme elevations occurred in a small number of participants, which is why the FDA label requires liver function testing before starting and periodically during treatment. Veozah is contraindicated in women with moderate or severe hepatic impairment and should be used cautiously with CYP1A2 inhibitors such as fluvoxamine, because fezolinetant is metabolized by CYP1A2.

How to Switch Between Premarin and Veozah

No published clinical trial has directly studied a Premarin-to-Veozah or Veozah-to-Premarin switch protocol. The framework below is based on each drug's pharmacokinetics, mechanism, and FDA labeling, and has been reviewed by the WomanRx editorial board.

Switching from Premarin to Veozah

You do not need a washout period. CEE has a half-life of roughly 17 hours for equilin and shorter for other conjugated fractions. By the time you stop Premarin and start Veozah the next day, there is no pharmacokinetic overlap that would cause an interaction. However, your hot flashes may temporarily worsen in the first one to two weeks after stopping estrogen, before Veozah reaches its full steady-state effect at approximately two weeks of daily dosing.

Practical steps:

1. Confirm your liver function tests are normal before starting Veozah.
2. Stop Premarin on a given day.
3. Start Veozah 45 mg the following morning, with or without food.
4. Expect a possible two-week window of slightly increased hot flash frequency as the NK3 blockade builds.
5. If you were taking a progestogen with Premarin and had a uterus, you may discontinue the progestogen once Premarin is stopped, since Veozah has no estrogenic effect on the endometrium.

Switching from Veozah to Premarin

Fezolinetant has a half-life of approximately 10.5 hours, so it clears within 48 to 72 hours. No washout is required before starting CEE. If you have a uterus, you must start a progestogen alongside Premarin from day one, not after a delay.

Practical steps:

1. Stop Veozah.
2. Start Premarin 0.3 to 0.625 mg the next day, along with your progestogen if your uterus is intact.
3. Have a baseline mammogram current (within 12 months) before starting systemic estrogen.
4. Schedule a blood pressure check at 6 to 8 weeks: CEE can raise blood pressure in some women.

When No Switch Is Needed

Some women on Premarin for bone protection, GSM, or mood stabilization may wish to add Veozah when hot flashes persist despite adequate CEE dosing. This combination has not been formally studied, and there is no pharmacokinetic reason to expect a dangerous interaction, but the clinical evidence base for concurrent use is absent. Dose optimization of CEE (for example, moving from 0.3 to 0.625 mg, or switching from oral to transdermal estradiol) or addressing poor adherence is usually the first step before considering add-on Veozah.

Bone Health: A Critical Difference

Premarin has an FDA-approved indication for the prevention of postmenopausal osteoporosis. The WHI estrogen-alone arm showed a significant reduction in hip and total fracture rates in the CEE group. Veozah has no bone-protective mechanism and no fracture data. Women who switch from Premarin to Veozah for vasomotor symptom control should discuss whether they need a dedicated bone-protective agent (bisphosphonate, denosumab, or other) if they have osteopenia or osteoporosis, particularly if they were relying on CEE for dual vasomotor and bone benefit.

ACOG's guidance on osteoporosis prevention recommends baseline DEXA screening for all women at menopause if risk factors are present, or at age 65 universally.

Genitourinary Syndrome of Menopause (GSM): Another Gap

GSM includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs driven by low estrogen in the genitourinary tissues. Premarin, as systemic estrogen, helps GSM. Veozah does not act on genitourinary tissues at all. A woman who switches from CEE to Veozah for vasomotor symptoms may find her vaginal dryness or dyspareunia worsens over time. Local vaginal estrogen (estradiol cream, estradiol ring, or ospemifene for dyspareunia) can be used alongside Veozah without the systemic risks of oral CEE, since vaginal estrogen is minimally absorbed systemically at low doses. This is a distinction that matters for sexual health and quality of life, and it should be part of any switching conversation with your clinician.

Cost and Access Considerations

Premarin has been generic-adjacent for decades (though true generics of CEE are limited), and a 30-day supply commonly costs $30 to $80 with insurance. Veozah is a brand-only drug as of 2025, with a list price of approximately $550 to $600 per month, though manufacturer patient assistance programs exist. Insurance coverage for Veozah varies: some plans require prior authorization documenting a contraindication or inadequate response to hormone therapy. Women paying out of pocket should factor this into the switching decision.

A Practical "Right for You / Not Right for You" Summary

Premarin may be the better fit if you:

• Are postmenopausal with no contraindications to estrogen
• Also have vaginal dryness, GSM, or low bone density
• Had a hysterectomy (can use CEE without a progestogen)
• Are within 10 years of menopause onset and have cardiovascular risk factors that don't include stroke or DVT history

Veozah may be the better fit if you:

• Have a personal or oncologist-recommended contraindication to estrogen
• Had ER-positive breast cancer
• Have a history of DVT, PE, or stroke
• Prefer a hormone-free approach
• Have moderate-to-severe hot flashes as your primary symptom, without significant GSM

Neither drug is a good fit if you:

• Are still in early perimenopause with regular or only slightly irregular cycles and need contraception
• Have active liver disease (Veozah) or unexplained vaginal bleeding (Premarin without evaluation)
• Are pregnant (both are contraindicated)